52 Biggest Movers From Yesterday
$ACET
$AERC
$AIH
$ANNX
Biotechnology: Pharmaceutical Preparations
Health Care
Environmental Services
Utilities
Gainers
- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.
- MEI Pharma, Inc. (NASDAQ:MEIP) jumped 37.6% to settle at $3.37. MEI Pharma and Kyowa Kirin Co announced data from the pivotal Phase 2 TIDAL studyof zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies.
- Pioneer Power Solutions, Inc. (NASDAQ:PPSI) shares gained 32.5% to close at $10.11 after dipping 27% on Monday.
- NuZee, Inc. (NASDAQ:NUZE) gained 31.4% to settle at $4.65.
- ImmunoGen, Inc. (NASDAQ:IMGN) jumped 29.9% to settle at $6.17 in reaction to positive topline data from the SORAYA trial of mirvetuximab soravtansine for ovarian cancer. The trial is evaluating mirvetuximab as monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Roche Holdings AG's (OTC:RHHBY) Avastin (bevacizumab).
- Gritstone bio, Inc. (NASDAQ:GRTS) gained 25.7% to close at $13.20 after the company announced the SARS-CoV-2 T cell epitopes administered within its self-amplifying mRNA COVID-19 vaccines are minimally impacted by the omicron variant.
- Context Therapeutics Inc. (NASDAQ:CNTX) shares rose 23.3% to close at $6.88 after climbing 9% on Monday.
- Clene Inc. (NASDAQ:CLNN) gained 22.4% to settle at $5.69.
- Seres Therapeutics, Inc. (NASDAQ:MCRB) jumped 22% to settle at $10.76. Seres Therapeutics said first patient was enrolled in Phase 1b study of SER-155 investigational microbiome therapeutic to reduce the risk of antibiotic-resistant bacterial infections and graft-versus-host disease.
- ImmunityBio, Inc. (NASDAQ:IBRX) gained 21.9% to settle at $7.79.
- Cyteir Therapeutics, Inc. (NASDAQ:CYT) gained 20% to close at $16.61. Cyteir Therapeutics, last month, posted a Q3 loss of $0.33 per share.
- Molecular Partners AG (NASDAQ:MOLN) climbed 17.8% to settle at $14.01 after the company confirmed retained activity of ensovibep on the positions mutated in emerging omicron variant of SARS-CoV-2 in vitro.
- Vir Biotechnology, Inc. (NASDAQ:VIR) gained 17.1% to close at $47.42 after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $135 to $200.
- Terns Pharmaceuticals, Inc. (NASDAQ:TERN) surged 16.3% to settle at $7.55. Terns Pharmaceuticals, last month, posted a Q3 loss of $0.47 per share.
- Armata Pharmaceuticals Inc. (NYSE:ARMP) jumped 15.4% to close at $4.96.
- Annexon, Inc. (NASDAQ:ANNX) surged 15.1% to settle at $16.29. HC Wainwright & Co. initiated coverage on Annexon with a Buy rating and announced a price target of $40.
- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) jumped 14.3% to close at $27.32. JMP Securities initiated coverage on Crinetics Pharmaceuticals with a Market Outperform rating and announced a price target of $43.
- Navigator Holdings Ltd. (NYSE:NVGS) gained 14.1% to close at $9.13. Navigator Holdings posted Q3 EPS of $0.02.
- ERYTECH Pharma S.A. (NASDAQ:ERYP) gained 13.6% to close at $2.72 after the company secured US patent directed to sequential use of methioninase & asparaginase against solid tumors.
- Adicet Bio, Inc. (NASDAQ:ACET) surged 11.8% to close at $10.64.
- Paltalk, Inc. (NASDAQ:PALT) rose 11.7% to settle at $4.02.
- Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) gained 9.8% to close at $5.72 after the company announced issuance of two new patents for JATENZO.
- Chimerix, Inc. (NASDAQ:CMRX) gained 7.3% to close at $6.29.
- ContraFect Corporation (NASDAQ:CFRX) gained 5.9% to close at $3.41.
Check out these big penny stock gainers and losers
Losers
- AeroClean Technologies, Inc. (NASDAQ:AERC) shares dipped 78.7% to close at $25.00 on Tuesday after jumping around 45% on Monday.
- Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) shares fell 60.1% to close at $8.75 after the company announced first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250.
- TG Therapeutics, Inc. (NASDAQ:TGTX) dipped 34.9% to settle at $15.20 after the company reported the FDA plans to host a meeting of the Oncologic Drugs Advisory Committee in connection with its review of the pending BLA/sNDA for the combination of ublituximab and UKONIQ.
- Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) dipped 28.5% to close at $2.86 after surging over 91% on Monday.
- Local Bounti Corporation (NASDAQ:LOCL) fell 27% to close at $6.57.
- Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) dropped 23.1% to settle at $2.56. Aesthetic Medical Intl, last month, posted Q2 sales of $34.7 million.
- JX Luxventure Limited (NASDAQ:LLL) dropped 22% to settle at $2.66.
- Array Technologies, Inc. (NASDAQ:ARRY) fell 21.2% to close at $18.01 after the company reported a proposed private offering of $325 million of convertible senior notes.
- Barnes & Noble Education, Inc. (NYSE:BNED) fell 21% to close at $7.02 after the company reported worse-than-expected Q2 EPS and sales results.
- Dillard's, Inc. (NYSE:DDS) dipped 19.4% to close at $273.90.
- RLX Technology Inc. (NYSE:RLX) fell 18.9% to settle at $4.11.
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) fell 17.5% to close at $6.68. NRx Pharmaceuticals rose 20% on Monday after the company announced positive data from its ZYESAMI study.
- Palatin Technologies, Inc. (NYSE:PTN) shares fell 16.4% to close at $0.7149 after gaining more than 50% on Monday.
- Lizhi Inc. (NASDAQ:LIZI) fell 15.9% to close at $2.12 after the company reported worse-than-expected Q3 sales results.
- Biofrontera Inc. (NASDAQ:BFRI) fell 15.6% to close at $5.99 following Q3 results.
- Invacare Corporation (NYSE:IVC) dropped 15.4% to settle at $2.74.
- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) fell 15.4% to close at $2.14. Unicycive Therapeutics recently updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate).
- CTI BioPharma Corp. (NASDAQ:CTIC) dropped 15.4% to settle at $2.25. CTI BioPharma announced extension of FDA review period for pacritinib in myelofibrosis with severe thrombocytopenia.
- Dada Nexus Limited (NASDAQ:DADA) dipped 15.4% to close at $18.07. Dada Group and Jiajiayue Group jointly launched the Online and Offline Chile E-commerce Festival.
- ION Acquisition Corp 2 Ltd. (NYSE:IACB) fell 15.2% to settle at $7.95
- Pasithea Therapeutics Corp. (NASDAQ:KTTA) fell 15.1% to close at $3.61.
- Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) declined 15% to settle at $3.79.
- StoneX Group Inc. (NASDAQ:SNEX) dropped 14.6% to close at $56.17 following Q4 results.
- BlueCity Holdings Limited (NASDAQ:BLCT) fell 14.6% to close at $1.81.
- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) dipped 14.1% to settle at $2.87. Bluejay Diagnostics, last month, priced its IPO at $10 per unit.
- cbdMD, Inc. (NASDAQ:YCBD) fell 13.4% to close at $1.68. CbdMD shares jumped 30% on Monday after the company announced a multi-year exclusive agreement with Amify, an Amazon.com platform partner.
- Apogee Enterprises, Inc. (NASDAQ:APOG) fell 10.3% to close at $41.30.
- Baozun Inc. (NASDAQ:BZUN) dipped 7.1% to close at $13.79 as the company reported third-quarter FY21 revenue growth of 3.8% year-on-year to $294.7 million (RMB1.9 billion), missing the consensus of $303.5 million.